venBio Partners LLC Takes Position in Lyell Immunopharma, Inc. $LYEL

venBio Partners LLC acquired a new stake in Lyell Immunopharma, Inc. (NASDAQ:LYEL) in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund acquired 337,697 shares of the company’s stock, valued at approximately $4,744,643,000. Lyell Immunopharma comprises 0.9% of venBio Partners LLC’s holdings, making the stock its 7th biggest position.

Several other large investors have also modified their holdings of the company. ARCH Venture Management LLC boosted its stake in Lyell Immunopharma by 51.5% during the 3rd quarter. ARCH Venture Management LLC now owns 2,759,072 shares of the company’s stock worth $44,807,000 after purchasing an additional 938,438 shares during the period. GSK plc purchased a new position in Lyell Immunopharma during the 4th quarter worth $46,560,000. MWG Caph Ltd acquired a new position in Lyell Immunopharma in the fourth quarter valued at $31,030,000. Vanguard Group Inc. increased its stake in Lyell Immunopharma by 76.0% in the third quarter. Vanguard Group Inc. now owns 779,004 shares of the company’s stock valued at $12,651,000 after purchasing an additional 336,378 shares during the period. Finally, Acadian Asset Management LLC raised its holdings in shares of Lyell Immunopharma by 204.2% in the first quarter. Acadian Asset Management LLC now owns 660,899 shares of the company’s stock valued at $354,000 after buying an additional 443,614 shares during the last quarter. 66.05% of the stock is owned by institutional investors and hedge funds.

Lyell Immunopharma Stock Down 1.3%

Shares of LYEL opened at $14.61 on Friday. Lyell Immunopharma, Inc. has a 52-week low of $10.76 and a 52-week high of $45.00. The company has a 50-day simple moving average of $13.85 and a 200-day simple moving average of $18.02. The company has a market capitalization of $358.00 million, a PE ratio of -1.14 and a beta of -0.04.

Lyell Immunopharma (NASDAQ:LYEL) last released its quarterly earnings data on Thursday, August 6th. The company reported ($1.92) earnings per share for the quarter, beating the consensus estimate of ($1.94) by $0.02. Lyell Immunopharma had a negative return on equity of 91.62% and a negative net margin of 920,285.25%.The firm had revenue of $0.00 million during the quarter, compared to the consensus estimate of $0.00 million. On average, research analysts anticipate that Lyell Immunopharma, Inc. will post -7.2 EPS for the current year.

Wall Street Analysts Forecast Growth

LYEL has been the subject of a number of recent research reports. Royal Bank Of Canada set a $34.00 price objective on Lyell Immunopharma in a research report on Friday, August 14th. HC Wainwright reissued a “buy” rating and issued a $45.00 target price on shares of Lyell Immunopharma in a report on Tuesday, June 9th. B. Riley Financial assumed coverage on Lyell Immunopharma in a research note on Wednesday, July 22nd. They set a “buy” rating and a $44.00 price target for the company. Needham & Company LLC reaffirmed a “buy” rating and set a $44.00 price target on shares of Lyell Immunopharma in a report on Monday, June 15th. Finally, Citigroup reaffirmed a “market outperform” rating on shares of Lyell Immunopharma in a report on Friday, August 14th. One research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $40.86.

Lyell Immunopharma Company Profile

Lyell Immunopharma is a clinical-stage biotechnology company focused on developing next-generation T cell therapies for cancer. Leveraging a proprietary platform that combines cell therapy, gene editing and molecular discovery, Lyell seeks to overcome key barriers in the treatment of solid tumors. The company’s approach centers on engineering T cells to enhance their persistence, functionality and resistance to the immunosuppressive tumor microenvironment.

The company’s pipeline includes multiple autologous T cell programs engineered to target tumor-associated antigens in solid malignancies such as melanoma, ovarian and pancreatic cancers.